期刊文献+

喹诺酮类抗菌药的耐药性机制及研究进展 被引量:14

Advances in studies on quinolone resistance and its mechanisms
原文传递
导出
摘要 喹诺酮类抗菌药抗菌谱广,在临床上广泛应用于各种感染的治疗。喹诺酮类药物可通过阻断拓扑酶的生理功能继而干扰细菌的复制,从而起到抗菌的作用。也正是由于其广泛应用,近年来此类药物的耐药现象严重,且机制多样。综述了喹诺酮类药物的作用机制、耐药机制及其研究进展。 Quinolones have potential and broad antimicrobial activity on gram-positive and -negative bacteria in clinic, respectively. They could interfere the duplication of bacteria by blocking the physiologic function of DNA gyrase and DNA topoisomerase IV. So quinolones have been used worldwide against a variety of infections. As a result of their frequent use, bacterial resistance to quinolones has gradually developed and limited their therapeutic efficacy in infections. This article reviews the antibacterial and resistance mechanisms of quinolone based on the recent research advances.
出处 《药物评价研究》 CAS 2012年第3期199-203,共5页 Drug Evaluation Research
基金 江苏省省级科技创新与成果转化专项引导资金项目(BE2008672)
关键词 喹诺酮类药物 耐药性 耐药机制 quinolones drug resistance mechanisms of resistance
  • 相关文献

参考文献29

  • 1Mugnaini C,Pasquini S,Corelli F. The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry[J].Current Medicinal Chemistry,2009,(14):1746-1767.doi:10.2174/092986709788186156.
  • 2Drlica K,Malik M,Kerns R J. Quinolone-mediated bacterial death[J].Antimicrobial Agents and Chemotherapy,2008,(02):385-392.doi:10.1128/AAC.01617-06.
  • 3Sorlozano A,Gutierrez J,Jimenez A. Contribution of a new mutation in parE to quinolone resistance in extended-spectrum-beta-lactamase-producing Escherichia coli isolates[J].Journal of Clinical Microbiology,2007,(08):2740-2742.
  • 4Sun Z,Zhang J,Zhang X. Comparison of gyrA gene mutations between laboratory-selected ofloxacin-resistant Mycobacterium tuberculosis strains and clinical isolates[J].International Journal of Antimicrobial Agents,2008,(02):115-121.doi:10.1016/j.ijantimicag.2007.10.014.
  • 5Matrat S,Petrella S,Cambau E. Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones[J].Antimicrobial Agents and Chemotherapy,2007,(05):1643-1648.doi:10.1128/AAC.01282-06.
  • 6Wang Y,Huang W M,Taylor D E. Cloning and nucleotide sequence of the Campylobacter jejuni gyrA gene and characterization of quinolone resistance mutations[J].Antimicrobial Agents and Chemotherapy,1993,(03):457-463.
  • 7Gibreel A,Sjogren E,Kaijser B. Rapid emergence of high-level resistance to quinolones in Campylobacter jejuni associated with mutational changes in gyrA and parC[J].Antimicrobial Agents and Chemotherapy,1998,(12):3276-3278.
  • 8Kim H,Nakajima C,Yokoyama K. Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance[J].Antimicrobial Agents and Chemotherapy,2011,(08):3661-3667.
  • 9Bialek S,Lavigne J P,Chevalier J. Membrane efflux and influx modulate both multidrug resistance and virulence of Klebsiella pneumoniae in a Caenorhabditis elegans model[J].Antimicrobial Agents and Chemotherapy,2010,(10):4373-4378.
  • 10Kim K Y,Park J H,Kwak H S. Characterization of the quinolone resistance mechanism in foodborne Salmonella isolates with high nalidixic acid resistance[J].International Journal of Food Microbiology,2011,(01):52-56.

二级参考文献9

  • 1中华人民共和国卫生部医政司.全国临床检验操作规程(第2版)[M].南京:东南大学出版社,1995.460-462.
  • 2Chapman JS,Georgopapadakou NH. F1uorometric assay for fleroxacin uptake by bacterial cells.Antimicrob. Agents Chemother,1989;33(1):27.
  • 3Mortimer PGS, Piddock LJV.A comparison of methods used for measuring the accumulation of quinolones by Enterob-acteriaceae, Pseudomonas aeruginosa,and Staphylococcusa aureus.J Antimicrob Chemother,1991;28(2):639.
  • 4Nikaido H,Thanassi DG.Penetration of lipophilic agents with multiple protonation sites into bacterial cells:tetracyclines and fluoroquinones as examples. Antimicrob. Agents Chemother,1993;37(7):1393.
  • 5Li XZ, Livermaore DM, Nikaido H. Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa:Resistance to tetracycline,chloramphenical,and norfloxacin.Antimicrob.Agents Chemother,1994;38(8):1732.
  • 6Mc Murry LM,George AM,Levy SB.Active efflux of chloramphenicol in susceptible Escherichia coli strains and in multiple- antibiotic- resistant(Mar)mutant. AntimicrobAgents Chemother,1994;38(3):542.
  • 7Thanassi DG,Suh GSB,Nikaido H.Role of outer membrane barrier in efflux-mediated tetracycline resistance of Escherichia coli.J Bacteriol.1995;177(4):998.
  • 8Mccaffrey C,Bertasso A,Pace J, et al.Quinolone accumulation in Escherichia coli,Pseudomonas aeruginosa,and Staphylococcus. Antimicrob Agents Chemother,1992;36(4):1601.
  • 9Denis A,Moreau NJ.Mechanisms of quinolone resistance in clinic isolates: accumulation of sparfloxacin and fluoroquinolones of various hydrophobicity and analysis of membrane composition.Antimicrob Agents Chemother,1993;32(3):379.

共引文献7

同被引文献178

引证文献14

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部